Previous close | 1.9000 |
Open | 1.9000 |
Bid | 1.7500 |
Ask | 2.2500 |
Strike | 15.00 |
Expiry date | 2024-10-18 |
Day's range | 1.9000 - 1.9000 |
Contract range | N/A |
Volume | |
Open interest | 1 |
BioLife's (BLFS) latest product, CryoCase, is compatible with various downstream processing systems, including its own Signata CT-5.
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced the introduction of the CryoCase, an addition to its CellSeal product line.
On May 15, 2024, Todd Berard, the Chief Marketing Officer of BioLife Solutions Inc (NASDAQ:BLFS), executed a sale of 10,000 shares of the company.